BR112023006220A2 - Uso do extrato de mycobacterium tuberculosis - Google Patents

Uso do extrato de mycobacterium tuberculosis

Info

Publication number
BR112023006220A2
BR112023006220A2 BR112023006220A BR112023006220A BR112023006220A2 BR 112023006220 A2 BR112023006220 A2 BR 112023006220A2 BR 112023006220 A BR112023006220 A BR 112023006220A BR 112023006220 A BR112023006220 A BR 112023006220A BR 112023006220 A2 BR112023006220 A2 BR 112023006220A2
Authority
BR
Brazil
Prior art keywords
mycobacterium tuberculosis
extract
preventing
recurrence
tumor
Prior art date
Application number
BR112023006220A
Other languages
English (en)
Portuguese (pt)
Inventor
Horii Takayuki
Tanaka Takao
Original Assignee
Zeria Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharm Co Ltd filed Critical Zeria Pharm Co Ltd
Publication of BR112023006220A2 publication Critical patent/BR112023006220A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023006220A 2020-10-09 2021-10-08 Uso do extrato de mycobacterium tuberculosis BR112023006220A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020171491 2020-10-09
JP2020217698 2020-12-25
PCT/JP2021/037410 WO2022075458A1 (ja) 2020-10-09 2021-10-08 結核菌抽出物の新規用途

Publications (1)

Publication Number Publication Date
BR112023006220A2 true BR112023006220A2 (pt) 2023-05-09

Family

ID=81126102

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006220A BR112023006220A2 (pt) 2020-10-09 2021-10-08 Uso do extrato de mycobacterium tuberculosis

Country Status (12)

Country Link
US (1) US20230372476A1 (https=)
EP (1) EP4226939A4 (https=)
JP (1) JPWO2022075458A1 (https=)
KR (1) KR20230084177A (https=)
CN (1) CN116322771A (https=)
AU (1) AU2021357131A1 (https=)
BR (1) BR112023006220A2 (https=)
CA (1) CA3194869A1 (https=)
MX (1) MX2023004103A (https=)
TW (1) TW202228739A (https=)
WO (1) WO2022075458A1 (https=)
ZA (1) ZA202304219B (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS568320A (en) * 1979-07-04 1981-01-28 Chisato Maruyama Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
JPS5632489A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
JPH0680574A (ja) * 1991-11-05 1994-03-22 Kiichiro Ozaki 間接的癌治療剤
WO1998056941A1 (en) * 1995-12-12 1998-12-17 Tai Ho Chung Carbohydrate complex extracted from mycobacterium tuberculosis and process for the preparation thereof
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
GB0123756D0 (en) * 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
PT1618128E (pt) * 2003-04-23 2010-10-13 Max Planck Gesellschaft Vacina de tuberculose com eficácia melhorada
US20090208486A1 (en) * 2004-03-09 2009-08-20 Makoto Taketo Pharmaceutical composition comprising cxcr3 inhibitor
US20140199347A1 (en) * 2011-02-10 2014-07-17 University Of Louisville Research Foundation, Inc. Adjuvant compositions with 4-1bbl
JP5999639B2 (ja) * 2011-11-25 2016-09-28 国立研究開発法人産業技術総合研究所 免疫刺激因子担持微粒子
CN105999260B (zh) * 2016-05-13 2019-12-10 四川大学 氢氧化铝凝胶-氯化钠复合免疫佐剂及其制备方法和用途
JP7367906B2 (ja) 2019-04-10 2023-10-24 株式会社 シコク 手摺装置
EP4082577A4 (en) * 2019-12-27 2024-01-03 Zeria Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD AND DRUG

Also Published As

Publication number Publication date
AU2021357131A1 (en) 2023-05-25
AU2021357131A9 (en) 2025-03-13
EP4226939A4 (en) 2024-11-13
CA3194869A1 (en) 2022-04-14
EP4226939A1 (en) 2023-08-16
TW202228739A (zh) 2022-08-01
CN116322771A (zh) 2023-06-23
KR20230084177A (ko) 2023-06-12
JPWO2022075458A1 (https=) 2022-04-14
MX2023004103A (es) 2023-04-27
WO2022075458A1 (ja) 2022-04-14
US20230372476A1 (en) 2023-11-23
ZA202304219B (en) 2023-12-20

Similar Documents

Publication Publication Date Title
BR112019018863A8 (pt) Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
BR112020009655A8 (pt) Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica
BR112017000703A2 (pt) métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit
BR112019021822A2 (pt) Terapia de combinação
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
AR112328A1 (es) Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis
BR112018068906A2 (pt) composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
BR112023006364A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
MX391720B (es) Terapia combinada para tratar cáncer.
BR112022021956A2 (pt) Métodos, terapias e usos para o tratamento de câncer
BR112018069133A2 (pt) composições e métodos para penetração direcionada de partículas, distribuição, e resposta em tumores cerebrais malignos
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112015006176A8 (pt) método de tratamento de câncer em um indivíduo com necessidade de tratamento
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
BR112021012056A2 (pt) Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit
BR112018006817A2 (pt) método de tratamento do câncer
WO2019197605A3 (en) Drug combinations for use in the treatment of ras-mutant cancer
BR112015033053A2 (pt) método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit
BR112017026292A2 (pt) muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112022010072A2 (pt) Métodos que empregam óxido nítrico gasoso para inibir crescimento de tumor
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos